Written by Sean Kimbrough, Founder & Executive Director, Courage Against Cancer
Sourced from peer-reviewed and IRB-registered clinical research · Last updated July 21, 2026
Table of Contents
- Introduction
- Semantic Glossary
- What the Oncology Community’s Consensus Position Is
- How Evidence-Based Medicine Evaluates Off-Label Cancer Claims
- What Legitimate Ivermectin Research Actually Looks Like
- Additional Related Articles
- Frequently Asked Questions
- Conclusion
- Medical Disclaimer
Introduction
At Courage Against Cancer (CAC), we hear from cancer patients every week who have encountered viral claims about ivermectin as a cancer treatment — and who deserve clear, honest answers grounded in science. The short answer from the oncology community right now is this: ivermectin shows preclinical biological interest, but no validated clinical evidence supports its use as a cancer therapy in humans. Understanding why oncologists distinguish between laboratory findings and proven treatments is essential context before evaluating any study — including the heavily.
Semantic Glossary
Off-label use: Prescribing an FDA-approved drug for a purpose, dose, or population outside its approved indication cultures or animal models — before human trials. Promising preclinical results frequently fail to replicate in human patients.
Expression of Concern: A formal notice issued by a scientific journal flagging unresolved questions about a published study’s data integrity, methodology, or ethical oversight, without fully retracting the paper.
Observational study: A research design in which investigators record outcomes without controlling variables or randomizing participants, making it impossible to establish that a treatment caused an observed result.
What the Oncology Community’s Consensus Position Is
Major oncology institutions — including ASCO, the NCI, and the National Comprehensive Cancer Network — have not endorsed ivermectin as a cancer therapy. Their position is consistent and grounded in evidence hierarchy:
- No randomized controlled trials in humans have demonstrated ivermectin’s efficacy against cancer.
- **Self-reported symptom improvement-tumor activity.
- Antiparasitic mechanisms observed in laboratory models do not automatically translate into meaningful oncologic outcomes in human biology.
- Conflicts of interest in commercially motivated research require heightened scrutiny — particularly when study authors are affiliated with the sole seller of the product studied.
- Patient safety remains the primary concern; pursuing unvalid direct harm.
Oncologists are not dismissing the question — they are applying the same rigorous standards they use for every proposed therapy. Understanding what ivermectin is actually approved to treat helps patients appreciate why that process exists and why bypassing it carries real risk.
How Evidence-Based Medicine Evaluates Off-Label Cancer Claims
Evidence-based medicine (EBM) uses a structured hierarchy to assess whether a treatment works. Here is how ivermectin currently fits within that framework:
- Level 1 evidence (systematic reviews of randomized trials): Absent for ivermectin in oncology.
- Level 2 evidence (individual status and results should be independently verified at ClinicalTrials.gov.
- Level 3–4 evidence (observational studies, case series): The Hulscher et al. 2026 study falls here — and the journal itself issued an Expression of Concern citing unresolved questions about data verifiability, statistical reliability, and ethical oversight.
- Preclinical data (lab and animal models): The NCI has conducted separate, independent laboratory research into ivermectin’s biological properties — entirely unrelated to the Hulscher study or The Wellness Company.
Patients who want to understand what the science actually says about ivermectin and cancer will find important context for evaluating why this specific publication raises legitimate scientific concerns.
What Legitimate Ivermectin Research Actually Looks Like
Responsible scientific inquiry into ivermectin and cancer does exist — and it looks nothing like the Hulscher et al. study. Here is what credible research involves:
- Institutional oversight: IRB approval, independent data monitoring, and ethical review before a single patient is enrolled.
- No financial conflicts: Researchers and funders are not simultaneously selling the product under study.
- Prospective design: Outcomes are defined before data collection, not interpreted after self-reported results are gathered.
- Peer review integrity: Journals publishing findings have not issued Expressions of Concern about those findings.
- Transparent reporting: Data is verifiable and available for independent replication.
The NCI’s preclinical work and the NCT05318469 trial reflect this standard. Neither endorses ivermectin as a current cancer treatment. They represent the early, cautious steps of legitimate scientific investigation — the kind explored in what drug repurposing actually involves and how it might eventually apply to ivermectin in oncology. Patients who want to understand how to evaluate whether a cancer research study is trustworthy or commercially motivated will find that CAC’s educational resources offer a practical framework for that critical thinking.
Additional Related Articles
- 📖 Is the 2026 Ivermectin Cancer Study Real Evidence or a Red Flag? — The parent pillar article that investigates the Hulscher et al. study’s design, conflicts of interest, and the journal’s Expression of Concern in full.
- 📖 What the NCI’s Ivermectin Research Actually Involves — and What It Doesn’t Claim — Clarifies the distinction between independent preclinical laboratory research and commercially promoted off-label cancer treatment claims.
- 📖 How to Talk to Your Oncologist About Complementary and Off-Label Treatments — A practical guide for patients who want to raise questions about alternative therapies without compromising their cancer care relationship.
Frequently Asked Questions
Q: Have any oncologists endorsed ivermectin for cancer treatment?
No major oncology institution or professional society has endorsed ivermectin as a cancer therapy. Individual physicians may prescribe it off-label, but off-label prescribing is not equivalent to clinical evidence of efficacy.
Q: Is the NCI researching ivermectin for cancer?
The NCI has conducted independent preclinical laboratory research examining ivermectin’s biological properties. This research is separate from the Hulscher et al. study and does not constitute NCI endorsement of ivermectin as a cancer treatment.
Q: Should I ask my oncologist about ivermectin?
Yes — open communication with your oncology team is always encouraged. Your oncologist can review your specific diagnosis, current treatment plan, and any potential interactions or risks before you make any decisions about off-label medications. Cancer patients looking for trustworthy information about experimental treatments and how to vet sources may also find it helpful to consult established patient advocacy organizations and academic cancer centers.
Conclusion
The oncology and evidence-based medicine communities share a consistent position: ivermectin has not been validated as a human cancer therapy. Preclinical signals are not clinical proof. One registered trial exists. Self-reported observational studies with conflicts of interest are not reliable guides for treatment decisions. CAC encourages every patient to bring these questions to their care team — and to evaluate viral claims with the same rigor science demands.
Medical Disclaimer
This article is produced by Courage Against Cancer (CAC) for educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Information presented here reflects publicly available scientific literature and professional consensus as understood at the time of writing and should not be used as a substitute for guidance from a licensed oncologist or qualified healthcare provider. Always consult your medical team before making any changes to your cancer treatment plan.
About This Content: This article was written and curated by CAC’s founder, drawing on peer-reviewed and IRB-registered clinical research. CAC is in the process of establishing a formal Medical Review Board and will update our content review process as reviewers join. This content is for educational purposes only and is not medical advice — always consult your healthcare team before making treatment decisions.